JP2013518808A - 骨形成タンパク質のｐＨを制御するための緩衝液 - Google Patents

骨形成タンパク質のｐＨを制御するための緩衝液 Download PDF

Info

Publication number
JP2013518808A
JP2013518808A JP2012529917A JP2012529917A JP2013518808A JP 2013518808 A JP2013518808 A JP 2013518808A JP 2012529917 A JP2012529917 A JP 2012529917A JP 2012529917 A JP2012529917 A JP 2012529917A JP 2013518808 A JP2013518808 A JP 2013518808A
Authority
JP
Japan
Prior art keywords
solution
bmp
item
solid composition
glycylglycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012529917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518808A5 (enExample
Inventor
デイビッド ハイル，
グレッグ ストローマイヤー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Publication of JP2013518808A publication Critical patent/JP2013518808A/ja
Publication of JP2013518808A5 publication Critical patent/JP2013518808A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2012529917A 2009-09-17 2010-09-17 骨形成タンパク質のｐＨを制御するための緩衝液 Pending JP2013518808A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24338309P 2009-09-17 2009-09-17
US61/243,383 2009-09-17
PCT/US2010/049229 WO2011035094A1 (en) 2009-09-17 2010-09-17 Buffers for controlling the ph of bone morphogenetic proteins

Publications (2)

Publication Number Publication Date
JP2013518808A true JP2013518808A (ja) 2013-05-23
JP2013518808A5 JP2013518808A5 (enExample) 2013-09-26

Family

ID=43037185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012529917A Pending JP2013518808A (ja) 2009-09-17 2010-09-17 骨形成タンパク質のｐＨを制御するための緩衝液

Country Status (7)

Country Link
US (3) US20110224410A1 (enExample)
EP (1) EP2352750B1 (enExample)
JP (1) JP2013518808A (enExample)
AU (1) AU2010295509A1 (enExample)
CA (1) CA2774024A1 (enExample)
ES (1) ES2387379T3 (enExample)
WO (1) WO2011035094A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533635A (ja) * 2019-05-16 2022-07-25 イントラクト、ファーマ、リミテッド 安定剤としてジペプチドを含むタンパク質組成物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
CN114276407B (zh) * 2021-12-29 2023-08-15 浙江旅游职业学院 一种采用ph偏移技术从骨或壳内提取蛋白质的设备及方法
CN116549656A (zh) * 2023-05-25 2023-08-08 深圳奥礼生物科技有限公司 一种提高司美格鲁肽在肠道中稳定性的组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023123A1 (en) * 1998-10-19 2000-04-27 Synthes Ag Chur Hardenable ceramic hydraulic cement
WO2001078687A1 (en) * 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
EP1348450A2 (en) * 2002-03-29 2003-10-01 Ethicon, Inc. Bone replacement materials utilizing bioabsorbable liquid polymers
EP1374905A1 (en) * 2002-06-25 2004-01-02 Ethicon, Inc. Injectable microdispersions for medical applications

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US6919308B2 (en) 1988-04-08 2005-07-19 Stryker Corporation Osteogenic devices
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
CA2085134C (en) 1990-06-15 2003-03-18 Carnegie Institution Of Washington Gdf-1
US6949505B1 (en) 1991-03-11 2005-09-27 Curis, Inc. Morphogen-induced dendritic growth
US6800603B2 (en) 1991-03-11 2004-10-05 Curis, Inc. Morphogen-induced neural cell adhesion
US6506729B1 (en) 1991-03-11 2003-01-14 Curis, Inc. Methods and compositions for the treatment and prevention of Parkinson's disease
US5656593A (en) 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US5674844A (en) 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5849686A (en) 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
DK0625989T3 (da) 1992-02-12 2000-06-26 Bioph Biotech Entw Pharm Gmbh DNA-sekvenser kodende for hidtil ukendte vækst-/differentieringsfaktorer
CA2147598A1 (en) 1992-11-03 1994-05-11 Stryker Corporation Op-3-induced morphogenesis
CA2153653C (en) 1993-01-12 2010-12-07 Se-Jin Lee Growth differentiation factor-9
EP0690871A4 (en) 1993-01-12 1999-10-20 Univ Johns Hopkins Med GROWTH DIFFERENTIATION FACTOR-5
DK0690873T3 (da) 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
WO1994026892A1 (en) 1993-05-12 1994-11-24 Genetics Institute, Inc. Bmp-11 compositions
JPH09501305A (ja) 1993-05-12 1997-02-10 ジェネティックス・インスティテュート・インコーポレイテッド Ｂｍｐ−１０組成物
WO1995001801A1 (en) 1993-07-09 1995-01-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-6
US6204047B1 (en) 1993-10-08 2001-03-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-10
JP3300500B2 (ja) 1993-10-12 2002-07-08 新日本製鐵株式会社 疲労強度、降伏強度および被削性に優れる熱間鍛造用鋼の製造方法
DE4334646C1 (de) 1993-10-12 1994-09-29 Quinting Friedhelm Durchsichtige Analog-Zeituhr
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
IL114397A0 (en) 1994-07-01 1995-10-31 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF-beta-family
EP1574577A3 (en) 1994-07-08 2006-06-14 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
AU1120295A (en) 1994-11-07 1996-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cartilage-derived morphogenetic proteins
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
EP0894004B2 (en) 1996-03-22 2007-02-21 Curis, Inc. Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US6958149B2 (en) 1998-10-06 2005-10-25 Stryker Corporation Repair of larynx, trachea, and other fibrocartilaginous tissues
CA2345024C (en) 1998-10-07 2009-05-19 Stryker Corporation Modified tgf-.beta. superfamily proteins
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
US6949251B2 (en) 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
CA2561809A1 (en) 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
CA2567405A1 (en) 2004-05-25 2005-12-08 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
WO2007087053A2 (en) 2005-12-22 2007-08-02 Centocor, Inc Bmp-7 variant compositions, methods and uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023123A1 (en) * 1998-10-19 2000-04-27 Synthes Ag Chur Hardenable ceramic hydraulic cement
WO2001078687A1 (en) * 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
EP1348450A2 (en) * 2002-03-29 2003-10-01 Ethicon, Inc. Bone replacement materials utilizing bioabsorbable liquid polymers
EP1374905A1 (en) * 2002-06-25 2004-01-02 Ethicon, Inc. Injectable microdispersions for medical applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014042813; Ｊｏｕｒｎａｌ　ｏｆ　Ｂｉｏｍｅｄｉｃａｌ　Ｍａｔｅｒｉａｌｓ　Ｒｅｓｅａｒｃｈ，　２００２，　Ｖｏｌ．６２，　Ｎｏ．２，　ｐ．１６９-１７４ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533635A (ja) * 2019-05-16 2022-07-25 イントラクト、ファーマ、リミテッド 安定剤としてジペプチドを含むタンパク質組成物
JP7696831B2 (ja) 2019-05-16 2025-06-23 イントラクト、ファーマ、リミテッド 安定剤としてジペプチドを含むタンパク質組成物

Also Published As

Publication number Publication date
AU2010295509A1 (en) 2012-04-19
CA2774024A1 (en) 2011-03-24
US20140336114A1 (en) 2014-11-13
ES2387379T3 (es) 2012-09-21
US20130172254A1 (en) 2013-07-04
WO2011035094A1 (en) 2011-03-24
EP2352750A1 (en) 2011-08-10
AU2010295509A2 (en) 2012-05-03
US20110224410A1 (en) 2011-09-15
EP2352750B1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
US20140336114A1 (en) Buffers for Controlling the pH of Bone Morphogenetic Proteins
JP4847634B2 (ja) 中枢神経系の虚血または外傷の機能的回復を増大させる方法
AU771382B2 (en) Methods and compositions for healing and repair of articular cartilage
JP5529754B2 (ja) Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体
US20070191276A1 (en) Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
JP5346657B2 (ja) 組織形態形成および活性を評価するための方法
JP2003506086A (ja) ＴＧＦ−βファミリーの単量体タンパク質
EP1148897B1 (en) Methods and compositions for healing and repair of articular cartilage
US20110224138A1 (en) Methods for treating pain induced by injuries and diseases of an articular joint
US20130190236A1 (en) BMP-7 Variants with Reduced Immunogenicity
AU773990B2 (en) Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
JPWO2010098421A1 (ja) 改善された保存安定性を有する組換えヒト骨形成蛋白質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150616